Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Algorae PharmaceuticalsASX:1AI 3-Year EPS without NRI Growth Rate is 20.60% as of Dec. 2025, which is 2% below its 10-year median of 21.00. The stock has 2 warning signs investors should review. Among 1,160 Biotechnology companies, Algorae Pharmaceuticals ranks better than 55.95% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 20.60% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 5.80% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 20.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Algorae Pharmaceuticals was 61.10% per year. The lowest was -26.00% per year. And the median was 21.00% per year.
Algorae Pharmaceuticals (ASX:1AI) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Algorae Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms
ASX:1AI vs VRTX, REGN, RVMD: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Algorae Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Algorae Pharmaceuticals 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Algorae Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.
Algorae Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 20.60% mean?
Algorae Pharmaceuticals (ASX:1AI) has a 3-Year EPS without NRI Growth Rate of 20.60% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Algorae Pharmaceuticals and its competitors. This is near median its historical median of 21.00. According to the industry distribution chart, Algorae Pharmaceuticals ranks #511 out of 1160 companies in the Biotechnology industry, placing it in the top 44.1%.
Is Algorae Pharmaceuticals' 3-Year EPS without NRI Growth Rate too high?
Algorae Pharmaceuticals' current 3-Year EPS without NRI Growth Rate of 20.60% is near median its 10-year median of 21.00. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Algorae Pharmaceuticals' value of 20.60% is 27.2% above this industry median. Based on the distribution chart, Algorae Pharmaceuticals ranks #511 out of 1160 companies in the Biotechnology industry, which is above the industry midpoint.
How does Algorae Pharmaceuticals' 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Algorae Pharmaceuticals ranks #511 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This puts Algorae Pharmaceuticals in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Algorae Pharmaceuticals' value of 20.60% is 27.2% above this benchmark. While the company's 10-year median is 21.00 vs. the industry median of 16.20, Algorae Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Algorae Pharmaceuticals's current 3-Year EPS without NRI Growth Rate of 20.60% is 27.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Algorae Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Algorae Pharmaceuticals's current 3-Year EPS without NRI Growth Rate is 20.60%, which is near median its own 10-year median of 21.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Algorae Pharmaceuticals stock overvalued right now?
Algorae Pharmaceuticals (ASX:1AI) has a current 3-Year EPS without NRI Growth Rate of 20.60%. The current 3-Year EPS without NRI Growth Rate is 20.60%, which is near median its 10-year median of 21.00 and 27.2% above the Biotechnology industry median of 16.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Algorae Pharmaceuticals (ASX:1AI), the current 3-Year EPS without NRI Growth Rate is 20.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer's disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:1AI has been successfully added to your 
